Key Performance
More- Earnings Score: N/A
- Momentum Score: 20
- True Yield: N/A
- Financial Health Score: N/A
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
TScan Therapeutics reported Q1 2026 financial results with net loss of $28.7 million and revenue of $1.0 million. The company announced multiple clinical milestones including early data from Cohort C of its Phase 1 ALLOHA trial expected in Q2 2026, planned Phase 3 initiation of TSC-101 in Q2 2026, and Phase 1 studies of TSC-102-A01 and TSC-102-A03 in H2 2026. Cash position of $128.1 million is expected to fund operations into H2 2027.
05/06/2026, 7:00 AM • GlobeNewswire
TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference
TScan Therapeutics, a clinical-stage biotech company developing TCR-engineered T cell therapies for cancer treatment, announced participation in the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026. The company reported completion of enrollment in Cohort C of its Phase 1 ALLOHA™ trial using a commercial-ready manufacturing process and received FDA clearance for investigational new drug applications for candidates TSC-102-A01 and TSC-102-A03.
04/08/2026, 7:00 AM • GlobeNewswire
TScan Therapeutics completed enrollment in Cohort C of its Phase 1 ALLOHA™ trial using a commercial-ready manufacturing process and received FDA clearance for investigational new drug applications for TSC-102-A01 and TSC-102-A03 candidates targeting CD45 for patients with HLA types A*01:01 and A*03:01. The company plans to share safety and chimerism data in Q2 2026 and launch a pivotal trial for TSC-101, while initiating Phase 1 studies for both TSC-102 candidates in the second half of 2026.
02/26/2026, 7:00 AM • GlobeNewswire
TScan Therapeutics reported promising results from its Phase 1 trial of TSC-101 for hematologic malignancies, showing improved relapse-free survival and no dose-limiting toxicities in patients undergoing bone marrow transplantation.
12/06/2025, 5:30 PM • GlobeNewswire
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points
Multiple biotech companies are advancing innovative immunotherapy and targeted treatments for blood cancers, with significant clinical trial progress and FDA approvals in acute myeloid leukemia (AML) and related hematologic conditions.
12/04/2025, 12:20 PM • Benzinga
TScan Therapeutics will present two abstracts at the ACR Convergence 2025, highlighting novel discoveries in T cell targets for autoimmune disorders like Ankylosing Spondylitis and Scleroderma using their TargetScan technology.
09/17/2025, 7:00 AM • GlobeNewswire
TScan Therapeutics to Participate in Upcoming Investor Conferences
TScan Therapeutics, a clinical-stage biotech company, announced participation in upcoming investor conferences and provided updates on its T cell receptor (TCR) therapies for cancer treatment, including ongoing clinical trials for hematologic malignancies and solid tumors.
09/03/2025, 7:00 AM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/02/2026
Company Profile
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.